Nasdaq · Biotech stocks database

NGEN — NervGen Pharma Corp.

NGEN (NervGen Pharma Corp.) stock: $2.05, $218.1M market cap, $16.1M cash, $202.0M EV, $204.4M fully diluted market cap. Next expected readout: Jul-27. Lead program: NVG-291 (Chronic Spinal Cord Injury), Phase 3. Data from Fully Diluted's biotech stocks database.

Share price

$2.05

Market cap

$218.1M

Cash

$16.1M

Enterprise value

$202.0M

Balance sheet

Cash	$16.1M
Debt	$0.0M
Net cash	$16.1M
Enterprise value	$202.0M
Basic shares	106.7M shares
Fully diluted shares	99.7M shares
Fully diluted market cap	$204.4M
Cash per share	$0.15

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading NGEN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 25 - Oct 6	NVG-291	Phase 3	Chronic Spinal Cord Injury	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	NVG-291
Lead indication	Chronic Spinal Cord Injury
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07799532	Phase 3	Not yet recruiting	Sponsor	NervGen Pharma	—	Chronic Spinal Cord Injury	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for NervGen Pharma on ClinicalTrials.gov

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego

NGEN — NervGen Pharma Corp.

Balance sheet

Price history

Upcoming catalysts

Pipeline

Active clinical trials